Mark J. Neveu, Ph.D.
Chief Scientific Officer, Wellome Sciences.
Dr. Neveu is the Chief Scientific Officer of Wellome Sciences located in Maine.
has over twenty-five years of exploratory research and translational development studies in both conventional and integrative healthcare.
Dr. Neveu was previously Chief Scientific Officer for NanoSynergy that utilized patented technology to improve the pharmacologic activity of nutraceuticals.
Prior to this, Dr. Neveu served as President and CEO of the National Foundation of Alternative Medicine founded by Congressman Berkley Bedell.
For eight years, Dr. Neveu supervised a mechanism based drug discovery laboratory at Pfizer that was responsible for both cancer and immunological diseases.
During this period, his
lab initiated novel therapeutic approaches for Tarceva™ (EGFR kinase inhibitor) and Pfizer's
first protein therapeutic Tremelimumab™ (anti-CTLA4) that was listed on Fortune's Top 10 list of cancer drugs.
He has been an honorary fellow of the Harvard School of Public Health and the Dana Farber Cancer Institute that utilized gene expression profiling to identify several novel tumor suppressor genes (e.g. Maspin) that have been developed for the diagnosis and treatment of cancer.
Dr. Neveu received his Ph.D. at the University of Wisconsin-Madison McArdle Laboratory for Cancer Research where he identified a family of Connexin genes (gap junctions) reversibly regulated by carcinogens.
collaborated with the Harvard Center for Risk Analysis and EPA/FDA
to develop toxicology regulatory guidelines based on these findings.
Dr. Neveu received his B.S. in Biochemistry and Nutrition from Virginia Tech where he conducted research on the chemical synthesis of anti-cancer natural products and environmental toxicology for the State of Virginia.